Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 827 clinical trials
Featured trial
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

This is a multicenter, open-label parallel-group to evaluate single oral doses of INCB000928 in participants with varying level of renal function or impairment.

body mass index
Accepts healthy volunteers
renal function
  • 0 views
  • 04 Oct, 2022
  • 4 locations
Featured trial
BAY-94-8862/16244 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

BAY-94-8862/16244 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

  • 1061 views
  • 25 Mar, 2021
  • 1 location
Featured trial
RENAL AID: Repository of Novel Analytes Leading to Autoimmune, Inflammatory, and Diabetic Nephropathies

RENAL AID: Repository of Novel Analytes Leading to Autoimmune, Inflammatory, and Diabetic Nephropathies

  • 218 views
  • 25 Mar, 2021
  • 1 location
Featured trial
(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis Patients.

(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis Patients.

  • 208 views
  • 08 Nov, 2020
  • 1 location
Featured trial
BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery

BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery

  • 92 views
  • 25 Mar, 2021
  • 1 location
Featured trial
Do you suffer from Hemorrhoids?

Do you suffer from Hemorrhoids?

  • 1577 views
  • 25 Mar, 2021
  • 1 location
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 764198 Administered Orally Once Daily for 12 Weeks in Patients With Focal Segmental Glomerulosclerosis

This study is open to adults with a type of kidney disease called primary focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three different doses of BI 764198 are …

  • 0 views
  • 28 Oct, 2022
  • 26 locations
Randomised, Double-blind, Placebo-controlled and Parallel Dose Group Trial to Investigate Efficacy and Safety of Multiple Doses of Oral BI 690517 Over 14 Weeks, Alone and in Combination With Empagliflozin, in Patients With Diabetic and Non-diabetic Chronic Kidney Disease

This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study. The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function in people with chronic kidney disease when taken alone …

  • 27 views
  • 27 Oct, 2022
  • 210 locations
Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function (SPARKLE)

The overall objective of this study is to evaluate the safety and diagnostic efficacy of Mangoral in liver MRI in participants with known or suspected focal liver lesions and severe renal

  • 0 views
  • 07 Oct, 2022
  • 44 locations
A Controlled, Open-label PA Efficacy and Safety Study in Imlifidase Desensitised Kidney Tx Patients With Positive XM Against a Deceased Donor Prior to Imlifidase Treatment, Including Non-comparative Registry and Concurrent Reference Cohorts (PAES)

An open-label post authorization efficacy and safety study evaluating graft failure-free survival at 1-year in highly sensitized end-stage renal disease (ESRD) patients with positive crossmatch

  • 0 views
  • 16 Oct, 2022
  • 6 locations